Interim data from open-label trial encouraging, but not conclusive
Antiviral therapy for heart transplant patients begun prior to receiving organs from hepatitis C virus (HCV) infected donors resulted in timelier transplantation, rapid viral suppression, and excellent early allograft function, interim results of an open-label study showed.